Agilent, ISB and ETH Zurich enter second phase of mapping complete human proteome

Ninth Annual World Conference of the Human Proteome Organization -- Agilent Technologies Inc. (NYSE:A) today announced that its collaboration with the Institute for Systems Biology (ISB) and the Swiss Federal Institute of Technology (ETH Zurich) for the mapping of the complete human proteome by mass spectrometry is entering its second phase.

“Agilent is a strong proponent of taking an integrated-biology approach to solving important health challenges”

On Sept. 20, the ISB and ETH Zurich announced completion of the first phase of this two-year project, including generating gold-standard reference mass spectra for each of 20,300 genes currently annotated as protein-encoding in the human genome. The project is expected to fuel research gains in biomarker discovery and validation, the search for protein-based diagnostic tests, personalized medicine and human health monitoring.

"Agilent is a strong proponent of taking an integrated-biology approach to solving important health challenges," said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division. "In recent years, we've devoted a great deal of effort to developing highly sensitive and selective proteomics tools for research, and we're delighted to see them being used to such great effect for this vital work."

The original collaboration, announced in October 2009, includes using Agilent triple quadrupole and quadrupole time-of-flight liquid chromatography/mass spectrometry (LC/MS) systems; nanoflow HPLC-Chip/MS systems; and protein analysis software at ISB in Seattle and ETH Zurich, to create a map of all human proteins.

The project is headed by ISB's Robert Moritz and ETH Zurich's Ruedi Aebersold, along with ISB President Leroy Hood. Support at ISB is by the National Human Genome Research Institute of the National Institutes of Health, which provided $2.7 million in direct funding under the American Recovery and Reinvestment Act of 2009. The project at ETH was supported by ERC Advanced Grant Proteomics v3.o funding for five years totaling EUR 2.4 million.

The data will be made accessible to the research community through the ISB/ETH SRMAtlas database (www.srmatlas.org) as part of the ISB/ETH PeptideAtlas (www.peptideatlas.org) project.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The crucial role of 'chaperones' in maintaining neuronal function